{"product_id":"phoixaz-4-ixazomib","title":"TAZEDX (Tazemetostat)","description":"\u003ch2\u003eAbout Tazemetostat\u003c\/h2\u003e\u003cp\u003eTazemetostat is a selective inhibitor of EZH2, administered orally.It is approved treatment for Follicular lymphoma and epithelioid sarcoma.\u003c\/p\u003e\u003ch2\u003eEpithelial Sarcoma\u003c\/h2\u003e\u003cp\u003eIndicated for metastatic or locally advanced epithelioid sarcoma not eligible for complete resection\u003c\/p\u003e\u003cp\u003e800 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eFollicular Lymphoma\u003c\/h2\u003e\u003cp\u003eIndicated for relapsed or refractory (R\/R) follicular lymphoma (FL) in patients whose tumors are positive for EZH2 mutation and who have received at least 2 prior systemic therapies\u003c\/p\u003e\u003cp\u003eAlso, indicated for R\/R FL in adults who have no satisfactory alternative treatment options\u003c\/p\u003e\u003cp\u003e800 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eDose reduction schedule\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eFirst reduction: 600 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 400 mg PO BID\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if unable to tolerate 400 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797945839659,"sku":"RL28202408161765","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-08-2175.jpg?v=1787022063","url":"https:\/\/xomeds.com\/products\/phoixaz-4-ixazomib","provider":"XOMEDS","version":"1.0","type":"link"}